Inflammatory Bowel Disease (IBD) Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Jan 2018| TMR126A| Transparency

Report Highlights

Global Inflammatory Bowel Disease (IBD) Treatment Market: Overview

Inflammatory bowel disease is a group of medical indication that causes chronic inflammation in the gastrointestinal tract. The inflammatory bowel disease mainly comprises of Ulcerative colitis and Crohn’s disease. The ulcerative colitis primarily affects the large intestine and anus and it causes the inflammation sores in the inner lining of colon and rectum. The Crohn’s disease affects any part of gastrointestinal tract and unlike ulcerative colitis, it affects all the layers of gastrointestinal walls. The ulcerative colitis is more prevalent than that of Crohn’s disease. The IBD affects equally in men and women and has prevalence and incidence rates in developed countries than that of developing and under developed countries. The exact cause of inflammatory bowel disease are not well understood however, the combination of several factors such as autoimmune disorders, genetic factors, lifestyle related risks factors such as smoking, sedentary lifestyle, lack of exercise are likely to contribute to the development of symptoms of inflammatory bowel disease. The common symptoms of inflammatory bowel disease includes the severe abdominal cramps and pain, persistent diarrhea, occasional rectal bleeding. The IBD has no permanent cure and requires the lifelong disease management and treatment. Several medications such as corticosteroids, aminosalicyclates, immunomodulators, and biologic drugs such as TNF inhibitors and up to certain extent antibiotic drugs are prescribed to relive the symptoms of these diseases.

Global Inflammatory Bowel Disease (IBD) Treatment Market: Trends and Opportunities

The global IBD treatment market is projected to be primarily driven by the new product development and approvals, rising use of biologic drugs and biosimilar drugs for the treatment of IBD. The high prevalence and increasing incidence of Crohn’s disease and Ulcerative colitis disease in developed countries has fueled the development of novel therapeutics drugs. Genetic factors are found to induce the one of the forms of IBD. The children of parents having IBD are more likely to develop the symptoms of IBD. Studies have shown that around 5 to 20 % of affected population have developed the symptoms of IBD through inherited genes from parents. The Risk of developing IBD is higher when both the parents are affected with IBD. Biopharmaceutical companies have made the significant investments in R&D activities and there are large number of pipeline products in different stages of clinical approvals which are likely to commercialize during the forecast period. Recent launch and approvals of new drugs in North America and Europe as well as in Japan is projected to fuel the demand for IBD treatment drugs in near future.

Global Inflammatory Bowel Disease (IBD) Treatment Market: Key Segments

The global IBD treatment market is broadly categorized into four segments based on drug class, disease indication, distribution channel and region. By drug class, the global market is segmented into TNF inhibitors, aminosalicyclates, immunomodulators, and corticosteroids. The TNF inhibitors accounted for leading share of global IBD treatment market in 2016 and is projected to gain its market share by the end of 2025. The large share and growth of TNF inhibitors is attributed to rising use of biologic drugs as second line of treatment and approvals in key markets. Aminosalicyclates drug class is the second leading share holder of global IBD treatment market and is projected to substantially lose its market share to corticosteroids and immunomodulators during the forecast period. In terms of distribution channel, the global IBD treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

By geography, the global IBD treatment market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. These regions have been further segmented by countries, drug class, and disease indication and distribution channels. North America and Europe accounted for leading share of global IBD treatment market and are projected to gain the market share by the end of 2025.

Global Inflammatory Bowel Disease (IBD) Treatment Market: Competitive Outlook k

The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global inflammatory bowel disease treatment market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc.

Global Inflammatory Bowel Disease Treatment Market is segmented as given below:

Global Inflammatory Bowel Disease Treatment Market, by Drug Class

TNF Inhibitors
Aminosalicyclates
Immunomodulators
Corticosteroids
Global Inflammatory Bowel Disease Treatment Market, by Disease Indication

Ulcerative Colitis
Crohn’s Disease
Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Inflammatory Bowel Disease Treatment Market, by Geography

North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East and Africa

  • Table 1 : Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
  • Table 2 : Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
  • Table 3 : Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 4 : Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Region, 2015–2025
  • Table 5 : North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country, 2015–2025
  • Table 6 : North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
  • Table 7 : North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
  • Table 8 : North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 9 : Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
  • Table 10 : Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
  • Table 11 : Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
  • Table 12 : Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 13 : Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
  • Table 14 : Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
  • Table 15 : Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
  • Table 16 : Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 17 : Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
  • Table 18 : Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
  • Table 19 : Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
  • Table 20 : Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 21 : Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
  • Table 22 : Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
  • Table 23 : Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
  • Table 24 : Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Figure 1 : Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, 2015– 2025
  • Figure 2 : Market Value Share, by Drug Class (2016)
  • Figure 3 : Market Value Share, by Disease Indication (2016)
  • Figure 4 : Market Value Share, by Distribution Channel (2016)
  • Figure 5 : Market Value Share, by Country (2016)
  • Figure 6 : Global Inflammatory Bowel Disease (IBD) Treatment Market Value Share analysis, by Drug Class, 2016 and 2025
  • Figure 7 : Global Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Drug Class, 2017–2025
  • Figure 8 : Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by TNF Inhibitors, 2015–2025
  • Figure 9 : Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Aminosalicyclates, 2015–2025
  • Figure 10 : Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Immunomodulators, 2015–2025
  • Figure 11 : Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2015–2025
  • Figure 12 : Global Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Disease Indication, 2016 and 2025
  • Figure 13 : Global Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2025
  • Figure 14 : Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Ulcerative Colitis, 2015–2025
  • Figure 15 : Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Crohn’s Disease, 2015–2025
  • Figure 16 : Global Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Distribution channel, 2016 and 2025
  • Figure 17 : Global Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness, by Distribution channel, 2017–2025
  • Figure 18 : Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2015–2025
  • Figure 19 : Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
  • Figure 20 : Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2015-2025
  • Figure 21 : Global Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Region, 2016 and 2025
  • Figure 22 : Global Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Region, 2017–2025
  • Figure 23 : North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
  • Figure 24 : North America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 25 : North America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 26 : North America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 27 : North America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Disease Indication, 2016 and 2025
  • Figure 28 : North America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 29 : North America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Drug Class, 2017–2025
  • Figure 30 : North America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2025
  • Figure 31 : North America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017–2025
  • Figure 32 : Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
  • Figure 33 : Europe Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
  • Figure 34 : Europe Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
  • Figure 35 : Europe Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 36 : Europe Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Disease Indication, 2016 and 2025
  • Figure 37 : Europe Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 38 : Europe Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Drug Class, 2017–2025
  • Figure 39 : Europe Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2025
  • Figure 40 : Europe Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017–2025
  • Figure 41 : Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
  • Figure 42 : Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
  • Figure 43 : Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
  • Figure 44 : Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 45 : Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Disease Indication, 2016 and 2025
  • Figure 46 : Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 47 : Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Drug Class, 2017–2025
  • Figure 48 : Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2025
  • Figure 49 : Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017–2025
  • Figure 50 : Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
  • Figure 51 : Latin America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
  • Figure 52 : Latin America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
  • Figure 53 : Latin America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 54 : Latin America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Disease Indication, 2016 and 2025
  • Figure 55 : Latin America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 56 : Latin America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Drug Class, 2017–2025
  • Figure 57 : Latin America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2025
  • Figure 58 : Latin America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017–2025
  • Figure 59 : Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
  • Figure 60 : Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
  • Figure 61 : Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
  • Figure 62 : Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 63 : Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Disease Indication, 2016 and 2025
  • Figure 64 : Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 65 : Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Drug Class, 2017–2025
  • Figure 66 : Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2025
  • Figure 67 : Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017–2025
  • Figure 68 : Global Inflammatory Bowel Disease (IBD) Treatment Market Share Analysis, by Company (2016)
  • Figure 69 : Shire Plc.’s Breakdown of Net Sales, by Business Segment
  • Figure 70 : Shire Plc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2016
  • Figure 71 : Shire Plc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 72 : Pfizer Inc.’s Breakdown of Net Sales, by Region, 2016
  • Figure 73 : Pfizer Inc.’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
  • Figure 74 : Pfizer Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 75 : Jonson & Johnson’s Breakdown of Net Sales, by Region, 2016
  • Figure 76 : Jonson & Johnson’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
  • Figure 77 : Jonson & Johnson’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 78 : Valeant Pharmaceutical's Breakdown of Net Sales, by Region, 2016
  • Figure 79 : Valeant Pharmaceutical's Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2016
  • Figure 80 : Valeant Pharmaceutical's R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 81 : Allergan Plc.’s Breakdown of Net Sales, by Business Segment
  • Figure 82 : Allergan Plc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2016
  • Figure 83 : Allergan Plc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 84 : Takeda Pharmaceutical’s Breakdown of Net Sales, by Region
  • Figure 85 : Takeda Pharmaceutical’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2016
  • Figure 86 : Takeda Pharmaceutical’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 87 : AbbVie Inc.’s Breakdown of Net Sales, by Region
  • Figure 88 : AbbVie Inc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
  • Figure 89 : AbbVie Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 90 : Novartis AG’s Breakdown of Net Sales, by Region
  • Figure 91 : Novartis AG’s Breakdown of Net Sales, by Business Segment
  • Figure 92 : Novartis AG’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2016
  • Figure 93 : Novartis AG’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 94 : UCB Inc.’s Breakdown of Net Sales, by Region
  • Figure 95 : UCB Inc.’s Breakdown of Net Sales, by Therapeutic Areas
  • Figure 96 : UCB Inc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2016
  • Figure 97 : UCB Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 98 : Biogen Inc.’s Breakdown of Net Revenue, by Region
  • Figure 99 : Biogen Inc.’s Breakdown of Net Sales, by Revenue Centers
  • Figure 100 : Biogen Inc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
  • Figure 101 : Biogen Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report